2-Aminophenoxazine-3-one Suppresses the Growth of Mouse Malignant Melanoma B16 Cells Transplanted into C57BL/6Cr Slc Mice

• Miyano-Kurosaki Naoko

  Department of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology

• Kurosaki Kunihiko

  Department of Legal Medicine, School of Medicine, Toho University

• Hayashi Michiko

  Department of Legal Medicine, School of Medicine, Toho University

• Takaku Hiroshi

  Department of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology

• Hayafune Masaaki

  Department of Life and Environmental Sciences, Faculty of Engineering, Chiba Institute of Technology

• Shirato Ken

  Laboratory of Physiological Sciences, Graduate School of Human Sciences, Waseda University

• Kasuga Teruhiko

  4th Department of Surgery, Tokyo Medical University

• Endo Takahiko

  Department of Forensic Medicine, Tokyo Medical University

• Tomoda Akio

  Department of Biochemistry and Research Institute of Immunological Treatment, Tokyo Medical University

抄録

Since phenoxazine is an essential structure of actinomycin D, which exerts a strong anticancer effect, we examined the anticancer effect of 2-aminophenoxazine-3-one (Phx-3) on mouse malignant melanoma B16 cells in vitro and in vivo. Phx-3 inhibited proliferation of the B16 cells in a dose-dependent manner in vitro. We furthermore studied the in vivo effects of Phx-3 on mouse malignant melanoma B16 cells transplanted in female C57BL/6Cr Slc mice. Treatment with Phx-3 (0.5 mg/kg) completely suppressed the growth of mouse malignant melanoma B16 cells transplanted in mice as compared with the control group. Phx-3 was found to exert few adverse effects, in terms of bodyweight loss, changes in serum levels of blood biochemical parameters such as aspartate transaminase (AST), alanine transaminase (ALT), blood urea nitrogen (BUN) and creatinine, dysfunction of the liver and the kidney examined by pathological methods, piloerection and wasting, when mice were treated with a dose of 0.5 mg/kg. These results suggest that Phx-3 may be used to treat patients affected by malignant melanoma in future.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 29 (11), 2197-2201, 2006

  公益社団法人 日本薬学会

キーワード

• phenoxazine
• mouse malignant melanoma B16 cell
• <i>in vivo</i> anti-tumor activity

詳細情報

• CRID: 1390282679604676864
• NII論文ID: 110004840391
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.29.2197
• ISSN: 13475215
• ISSN: 09186158
• NDL書誌ID: 8515875
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I8515875
• Web Site: http://www.jstage.jst.go.jp/article/bpb/29/11/29_11_2197/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2007158323
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可